A compound represented by the general formula, or a salt thereof, has exceptional CXCL10 inhibitory activity and is useful as a treatment agent for the prevention and/or treatment, etc., of diseases involving overproduction of CXCL10. In the formula: R.sup.1 is a C.sub.1-6 alkyl group, etc.; R.sup.2 is a hydrogen atom, etc.; R.sup.3 is a halogen atom, etc.; Z.sup.1, Z.sup.2, and Z.sup.3 are CH, etc.; X.sup.1 is CONH, etc.; ring A is a phenyl group, etc.; R.sup.4 is a halogen atom, etc.; and m is an integer of 0-5. ##STR00001##

A compound represented by the general formula, or a salt thereof, has exceptional CXCL10 inhibitory activity and is useful as a treatment agent for the prevention and/or treatment, etc., of diseases involving overproduction of CXCL10. In the formula: R.sup.1 is a C.sub.1-6 alkyl group, etc.; R.sup.2 is a hydrogen atom, etc.; R.sup.3 is a halogen atom, etc.; Z.sup.1, Z.sup.2, and Z.sup.3 are CH, etc.; X.sup.1 is CONH, etc.; ring A is a phenyl group, etc.; R.sup.4 is a halogen atom, etc.; and m is an integer of 0-5. ##STR00001##

The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: ##STR00001##
where: R independently represents a hydrogen atom, a halogen atom, a (C.sub.1-C.sub.3)alkyl group, a CN group, a hydroxyl group, a COOR.sub.1 group, a (C.sub.1-C.sub.3)fluoroalkyl group, a NO.sub.2 group, a NR.sub.1R.sub.2 group, or a (C.sub.1-C.sub.3)alkoxy group; R is a hydrogen atom, a halogen atom, a (C.sub.1-C.sub.3)alkyl group, a NO.sub.2 group, a (C.sub.1-C.sub.3)alkoxy group, or a NR.sub.1R.sub.2 group; and R.sub.1 and R.sub.2 are a hydrogen atom or a (C.sub.1-C.sub.3) alkyl group.

The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: ##STR00001##
where: R independently represents a hydrogen atom, a halogen atom, a (C.sub.1-C.sub.3)alkyl group, a CN group, a hydroxyl group, a COOR.sub.1 group, a (C.sub.1-C.sub.3)fluoroalkyl group, a NO.sub.2 group, a NR.sub.1R.sub.2 group, or a (C.sub.1-C.sub.3)alkoxy group; R is a hydrogen atom, a halogen atom, a (C.sub.1-C.sub.3)alkyl group, a NO.sub.2 group, a (C.sub.1-C.sub.3)alkoxy group, or a NR.sub.1R.sub.2 group; and R.sub.1 and R.sub.2 are a hydrogen atom or a (C.sub.1-C.sub.3) alkyl group.

The present disclosure is generally directed to the manufacture and use of compounds described herein for preventing, inhibiting or treating cancer, AIDS and/or premature aging, or the manufacture and use of a pharmaceutical composition comprising at least one of the compounds, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier for preventing, inhibiting or treating cancer, AIDS and/or premature aging.

The present disclosure is generally directed to the manufacture and use of compounds described herein for preventing, inhibiting or treating cancer, AIDS and/or premature aging, or the manufacture and use of a pharmaceutical composition comprising at least one of the compounds, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier for preventing, inhibiting or treating cancer, AIDS and/or premature aging.

The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

The invention relates to new compounds with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders, autoimmune disorders and metabolic disorders.

The invention relates to new compounds with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders, autoimmune disorders and metabolic disorders.